News
CVM
2.910
-4.28%
-0.130
Weekly Report: what happened at CVM last week (0420-0424)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 04/20 17:05
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 04/20 12:05
Weekly Report: what happened at CVM last week (0413-0417)?
Weekly Report · 04/20 09:47
*CEL-SCI to Offer Up to 3.44M Shrs
Dow Jones · 04/17 22:03
Weekly Report: what happened at CVM last week (0406-0410)?
Weekly Report · 04/13 09:50
Weekly Report: what happened at CVM last week (0330-0403)?
Weekly Report · 04/06 09:49
Weekly Report: what happened at CVM last week (0323-0327)?
Weekly Report · 03/30 09:50
Weekly Report: what happened at CVM last week (0316-0320)?
Weekly Report · 03/23 09:47
Weekly Report: what happened at CVM last week (0309-0313)?
Weekly Report · 03/16 09:47
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 03/09 12:05
Weekly Report: what happened at CVM last week (0302-0306)?
Weekly Report · 03/09 09:48
Weekly Report: what happened at CVM last week (0223-0227)?
Weekly Report · 03/02 09:47
Weekly Report: what happened at CVM last week (0216-0220)?
Weekly Report · 02/23 09:47
Cel-Sci GAAP EPS of -$0.68
Seeking Alpha · 02/18 20:44
*CEL-SCI Reports Fiscal 1Q 2026 Results
Dow Jones · 02/18 14:01
*CEL-SCI 1Q Loss/Shr 68c Vs. EPS $3.25 >CVM
Dow Jones · 02/18 14:01
Press Release: CEL-SCI Reports Fiscal First Quarter 2026 Results
Dow Jones · 02/18 14:00
Weekly Report: what happened at CVM last week (0209-0213)?
Weekly Report · 02/16 09:47
Weekly Report: what happened at CVM last week (0202-0206)?
Weekly Report · 02/09 09:48
More
Webull provides a variety of real-time CVM stock news. You can receive the latest news about CEL-SCI Corp through multiple platforms. This information may help you make smarter investment decisions.
About CVM
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).